

Special Issue

State-of-the-Art Cancer Biology and Therapeutics in Italy

Message from the Guest Editors

Cancer still represents one of the leading causes of death in the world and in Italy, there have been many advances in the treatment and care of cancer patients; new molecular targeted therapies and new knowledge in the molecular field represent an important step.

Understanding the basic biological processes, new biomarkers and their clinical characteristics will be fundamental for new therapies based on evaluating the individual response to treatments. Together, these data will open the way for more personalized medicine. This call for papers aims to collect high quality documents on the research areas in tumor diseases in Italy, with particular attention to studies on biological heterogeneity, their impact in the clinic, studies on molecular biology and studies on new molecular pathways. The use of multidisciplinary approaches is essential for the success of this field; therefore, contributions including interdisciplinary studies (epidemiology, genetics, molecular biology, cell biology, immunology and pharmacology) are strongly encouraged.

Guest Editors

Dr. Luca Pacini

Department of Medico-Surgical Sciences and Biotechnologies,
University of Rome "Sapienza", Roma, Italy

Dr. Umberto Malapelle

Department of Public Health, University of Naples Federico II, Naples,
Italy

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/140958

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).